Journal
JOURNAL OF PSYCHIATRIC RESEARCH
Volume 151, Issue -, Pages 667-675Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jpsychires.2022.04.008
Keywords
Bipolar disorder; Persistence; Pediatric; Adolescent; Young adult
Categories
Funding
- PCORI [K23MH100450]
- Demarest Lloyd, Jr. [667302]
- Johnson and Johnson [14/027,676, 10,245,271 B2]
- National Institute of Mental Health (NIMH) of the National Institutes of Health (NIH)
- Pfizer
- Shire
- Merck
- NeuroMetrix
- NIMH
- RLS Foundation
- Otsuka
- Axon Labs
- Boehringer-Ingelheim
- Cantor Colburn, Covance
- Cephalon
- Eli Lilly
- Novadel Pharma
- Sanofi-Aventis
- Sunovion
- Takeda
- UCB
- Xenoport
- Simons Center for the Social Brain
- American Academy of Child and Adolescent Psychiatry, The Israeli Society of ADHD
- Akili Interactive Labs, Arbor, Genomind, Ironshore
- Alcobra
- Enzymotec
- KemPharm
- European Union?sHorizon 2020 research and innovation programme
- AACAP, Feinstein Institute for Medical Research
- Headspace Inc.
- NIDA
- Roche TCRC Inc.
- NIH
- Biomarin, Bracket Global
- Cogstate
- Theravance
- Department of Psychiatry at MGH
- Tris
- Food & Drug Administration
- MGH Psychiatry Academy
- Jazz Pharma
- Department of Defense
- PamLab
- Ironshore
- AACAP
- Abbott
- APSARD, Arbor Pharmaceuticals
- AstraZeneca
- Celltech
- Children?s Hospital of Southwest
- Florida/Lee Memorial Health System, Cipher Pharmaceuticals Inc.
- Forest Research Institute, Fundacion Areces (Spain)
- Forest, Fundacio?n Dr.Manuel Camelo A.C.
- Juste Pharmaceutical Spain, Magceutics
- Medice Pharmaceuticals
- Merck, MGH Psychiatry Academy, MMC Pediatric, NARSAD
- NIDA, New River, NICHD
- Noven, Neurosearch
- Organon
- Prechter Foundation
- Quantia Communications
- Stanley Foundation
- UCB Pharma Inc., Vaya Pharma/Enzymotec
- Wyeth
Ask authors/readers for more resources
This study found that remission of pediatric bipolar I disorder is rare, with most patients continuing to experience high levels of morbidity into late adolescence and early adulthood.
Objective: To examine patterns of remission of pediatric bipolar I (BP-I) disorder attending to syndromatic, symptomatic, and functional outcomes from childhood to adolescent and young adult years. Methods: We analyzed data from a six-year prospective follow-up study of youths aged 6-17 years with BP-I disorder. Subjects were comprehensively assessed at baseline and subsequently at four, five, and six years thereafter. Assessments included structured diagnostic interviews and measures of psychosocial and educational functioning. Patterns of remission were calculated attending to whether syndromatic, symptomatic, and functional remission were achieved. Results: Kaplan-Meier failure functions revealed that the probability of functional recovery from pediatric BP-I disorder was very low. Of the 88 youths assessed, only 6% (N = 5) of the sample were euthymic with normal functioning during the year prior to their last follow-up assessment (average follow-up time = 5.8 +/- 1.8 years). Conclusions: These results provide compelling evidence of the high level of persistence of pediatric BP-I disorder. Symptomatic and functional remission were uncommon and most subjects continued to demonstrate high morbidity into late adolescence and early adulthood.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available